NPS hypoparathyroidism drug Natpara cleared with restrictions
This article was originally published in Scrip
Executive Summary
The FDA on 23 January gave its nod to NPS Pharmaceuticals, which is being acquired by Shire, to market Natpara, an injectable recombinant human parathyroid hormone replacement therapy, as a treatment for patients with hypoparathyroidism.